Mindset and InterVivo Solutions Announce Availability of First Preclinical Psychedelic Benchmark Data from COPE Program
June 14, 2021 07:30 ET
|
Mindset Pharma Inc.
TORONTO, June 14, 2021 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company"), a drug discovery and development company focused on creating...
Mindset Selects its Lead Clinical Candidate, MSP-1014, a Next Generation Psychedelic Medicine
June 03, 2021 07:00 ET
|
Mindset Pharma Inc.
MSP-1014 selected based on head-to-head comparison to psilocybin and its active metabolite psilocin MSP-1014 showed greater safety and efficacy in in vitro and in vivo preclinical models Cost...
Mindset Pharma Announces Promising Test Results of its Novel and Proprietary Psilocybin-Inspired Compounds
August 31, 2020 07:00 ET
|
Mindset Pharma Inc.
TORONTO, Aug. 31, 2020 (GLOBE NEWSWIRE) -- Mindset Pharma ("Mindset"), a leading drug discovery and development business focused on next-generation psychedelic medicines to treat neuropsychiatric...
Mindset Pharma Announces Filing of Groundbreaking Psilocybin Synthesis Patent
July 27, 2020 08:15 ET
|
Mindset Pharma Inc.
TORONTO, July 27, 2020 (GLOBE NEWSWIRE) -- Mindset Pharma (“Mindset”), a leading drug discovery business focused on developing next-generation psychedelic medicines, announces today the filing of a...
North Sur Resources and Mindset Pharma Announce Proposed Transaction to Accelerate Development of Medical Psychedelics Industry
June 29, 2020 16:15 ET
|
Mindset Pharma Inc.
VANCOUVER, British Columbia, June 29, 2020 (GLOBE NEWSWIRE) -- North Sur Resources Inc. (“North Sur”) and Mindset Pharma Inc. (“Mindset”) are pleased to announce that they have signed a binding...